TTD | Drug: D01OKE

Drug General Information
Drug ID	D01OKE
Former ID	DNC011936
Drug Name	NILVADIPINE
Drug Type	Small molecular drug
Indication	Discovery agent		Phase 3	[524577]
Formula	C19H19N3O6
Canonical SMILES	CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C<br />(=O)OC(C)C
InChI	1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
InChIKey	FAIIFDPAEUKBEP-UHFFFAOYSA-N
CAS Number	CAS 75530-68-6
PubChem Compound ID	4494
SuperDrug ATC ID	C08CA10
Target and Pathway
Target(s)	Voltage-dependent L-type calcium channel alpha-1D subunit	Target Info	Inhibitor	[533081]
Target(s)	Voltage-dependent L-type calcium channel subunit alpha-1C	Target Info	Inhibitor	[533081]
KEGG Pathway	MAPK signaling pathway
	Calcium signaling pathway
	cGMP-PKG signaling pathway
	cAMP signaling pathway
	Cardiac muscle contraction
	Adrenergic signaling in cardiomyocytes
	Vascular smooth muscle contraction
	Circadian entrainment
	Retrograde endocannabinoid signaling
	Glutamatergic synapse
	Cholinergic synapse
	Serotonergic synapse
	GABAergic synapse
	Dopaminergic synapse
	Insulin secretion
	GnRH signaling pathway
	Oxytocin signaling pathway
	Type II diabetes mellitus
	Carbohydrate digestion and absorption
	Alzheimer's disease
	Amphetamine addiction
	Hypertrophic cardiomyopathy (HCM)
	Arrhythmogenic right ventricular cardiomyopathy (ARVC)
	Dilated cardiomyopathyhsa04010:MAPK signaling pathway
	Long-term potentiation
	Dilated cardiomyopathy
NetPath Pathway	IL2 Signaling Pathway
PANTHER Pathway	Alzheimer disease-amyloid secretase pathway
	Nicotinic acetylcholine receptor signaling pathway
	5HT2 type receptor mediated signaling pathway
	Beta1 adrenergic receptor signaling pathway
	Beta2 adrenergic receptor signaling pathway
	Oxytocin receptor mediated signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
	Oxytocin receptor mediated signaling pathway
	Nicotine pharmacodynamics pathway
PathWhiz Pathway	Muscle/Heart Contraction
Reactome	Adrenaline,noradrenaline inhibits insulin secretion
	NCAM1 interactions
	Regulation of insulin secretionR-HSA-400042:Adrenaline,noradrenaline inhibits insulin secretion
	Regulation of insulin secretion
WikiPathways	Calcium Regulation in the Cardiac Cell
	Arrhythmogenic Right Ventricular Cardiomyopathy
	Alzheimers Disease
	NCAM signaling for neurite out-growth
	Integration of energy metabolismWP536:Calcium Regulation in the Cardiac Cell
	Integration of energy metabolism
	Nicotine Activity on Chromaffin Cells
References
Ref 524577	ClinicalTrials.gov (NCT02017340) A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease. U.S. National Institutes of Health.
Ref 533081	J Med Chem. 1989 Oct;32(10):2399-406.Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.

Drug Information